Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11683221 | 0.94 | BRAF (0.53) | MEN1KMT2AALDH1A1LMNACYP3A4 | |
| SCHEMBL10246421 | 0.90 | MEN1 (0.59) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL11690054 | 0.87 | TDP1 (0.57) | MEN1KMT2AALDH1A1LMNACYP3A4 | |
| SCHEMBL11683094 | 0.84 | TDP1 (0.53) | MEN1KMT2AALDH1A1LMNACYP3A4 | |
| SCHEMBL11683829 | 0.84 | ALDH1A1 (0.60) | MEN1KMT2AALDH1A1LMNACYP3A4 | |
| SCHEMBL1353032 | 0.83 | MEN1 (0.56) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL1315721 | 0.81 | TDP1 (0.59) | ALDH1A1CYP3A4TDP1MAPTPOLB | |
| SCHEMBL28566263 | 0.80 | WDR5 (0.60) | MEN1KMT2AALDH1A1LMNACYP3A4 | |
| SCHEMBL559830 | 0.80 | VCAM1 (0.64) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL30525281 | 0.80 | VCAM1 (0.64) | MEN1KMT2AALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2013-10-03 | — | — | US | disclosed |
| WO-2012059442-A2 | NEUROTRYPSIN INHIBITORS | NEUROTUNE AG (CH) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261130-A1 | NEUROTRYPSIN INHIBITORS | MTPN, CHRNA7, CHRNA10 | MEN1 3294/4885KMT2A 3851/4885ALDH1A1 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.